Full-Time

Software Engineer 2

Autonomous Lab

Ginkgo Bioworks

Ginkgo Bioworks

501-1,000 employees

Platform for cell programming and engineering

Compensation Overview

$85.6k - $120.2k/yr

+ Stock awards

No H1B Sponsorship

Boston, MA, USA

In Person

On-site attendance in the Boston office is required Monday through Friday. Relocation assistance is available.

Bachelor's, Master's

Category
Software Engineering (1)
Required Skills
LLM
Kubernetes
Microsoft Azure
Python
React.js
Software Testing
Git
Postgres
RDBMS
Data Engineering
TypeScript
AWS
Observability
REST APIs
LangChain
Data Modeling
Robotics
DevOps
Operations Research
Google Cloud Platform

Get referred to Ginkgo Bioworks

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Computer Science, Software Engineering, Electrical Engineering, Bioinformatics, or a related technical field, or equivalent practical experience.
  • Some professional software development experience, including work on team-owned codebases in a production setting, such as internships, academic research, or full-time employment.
  • Proficiency in Python.
  • Ability to reason about code across multiple files and components.
  • Familiarity with version control using Git and collaborative development workflows.
  • Strong communication skills and eagerness to collaborate with engineers and non-engineers alike.
Responsibilities
  • Scope and deliver well-defined features and components end-to-end with minimal guidance.
  • Write clean, readable, maintainable code and apply coding principles such as DRY and SOLID with guidance from senior teammates.
  • Recognize and follow established architectural patterns and contribute improvements as familiarity with the codebase grows.
  • Identify and communicate dependencies and potential blockers proactively.
  • Use AI agents and tooling to accelerate development while applying sound engineering judgment.
  • Participate constructively in technical design discussions and code reviews.
  • Work effectively with scientists, operators, and cross-functional partners to understand requirements and deliver solutions.
  • Ask questions, document decisions, and communicate progress clearly with the team.
  • Write unit and integration tests and consider edge cases and error conditions.
  • Address bugs and failing tests promptly and contribute to software quality.
  • Build logging, error handling, and observability into shipped software.
  • Develop expertise in the team's technical domain and the broader Catalyst platform.
  • Seek and act on feedback from peers and senior engineers and contribute mentorship to more junior teammates over time.
Desired Qualifications
  • Familiarity with laboratory automation, robotics, or scientific instrumentation.
  • Exposure to agentic systems, large-language-model-backed applications, or tool-use frameworks such as LangChain, MCP, and function calling.
  • Familiarity with scheduling, optimization, or operations research concepts.
  • Experience with hardware communication protocols or low-level systems programming.
  • Experience with specialized device software libraries such as HL8, Terapagos, and Stratum v2.
  • Familiarity with relational databases, especially PostgreSQL, and writing or modifying queries.
  • Exposure to Kubernetes, cloud infrastructure such as GCP, AWS, or Azure, or CI/CD pipelines.
  • Familiarity with REST API design and development.
  • Experience with TypeScript, React, or comparable frontend frameworks.
  • Proficiency with Git and experience working within agile methodologies.
  • Familiarity with additional programming languages relevant to the candidate's area of interest, such as TypeScript and React.

Ginkgo Bioworks offers a platform-based approach to cell programming for diverse industries such as food, agriculture, pharma, and chemicals. Its Foundry is an automated lab system that designs, builds, and tests engineered organisms, while the Codebase is a growing library of genetic parts and experimental data that informs new projects, all tied together by a Design-Build-Test-Learn loop for fast prototyping. The company earns revenue from Foundry-based R&D services and from Downstream Value, which can include royalties, milestone payments, or equity in partner companies. Its goal is to make biology easier to engineer and speed up the development of biological products through end-to-end tooling and data-driven workflows.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2009

Get referred to Ginkgo Bioworks

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 3, 2026 Perimeter spin-off and $60 million proceeds sharpened focus on autonomy.
  • Invaio's February 18, 2026 crop-protection deal expands Ginkgo into agricultural manufacturing.
  • Ginkgo cut 2026 first-half cash burn to $93 million and held $389 million liquidity.

What critics are saying

  • Q2 2026 revenue fell 48% to $20 million, exposing weak commercial demand.
  • Management gave no revenue guidance on August 5, 2026, hiding autonomous-lab adoption speed.
  • At $125 million-$150 million 2026 cash burn, Ginkgo risks existential dilution before traction.

What makes Ginkgo Bioworks unique

  • Ginkgo's Nebula and Cloud Lab turn wet labs into software-managed infrastructure.
  • OpenAI's GPT-5 collaboration on February 5, 2026 validated autonomous experimentation at scale.
  • The company bundles robotics, software, and strain libraries across pharma, agriculture, and industrial biology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Unlimited paid time off

Comprehensive health and parental leave benefits

Flexible work options

Commuter benefits

State-of-the-art labs, work spaces, and conference rooms

Competitive 401K contribution

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

0%
Yahoo Finance
May 10th, 2026
Ginkgo Bioworks pivots to autonomous labs as Q1 revenue falls 49% to $19M

Ginkgo Bioworks is refocusing on autonomous laboratories following the divestiture of its biosecurity business, which closed on 3 April. The biosecurity spin-off created a new company called Perimeter and brought in $60 million, with Ginkgo retaining a shareholding. CEO Jason Kelly said the company's 2026 investment priorities centre on winning the autonomous lab category through running services on its Boston-based Nebula system and selling autonomous lab systems to early adopters like Pacific Northwest National Laboratory. First-quarter revenue from continuing operations fell 49% year-over-year to $19 million, though excluding a $7.5 million non-cash item from 2025, the decline was 37%. Operating expenses dropped significantly, with research and development costs down 38% to $30 million and general and administrative expenses falling 35% to $13 million.

Yahoo Finance
Mar 15th, 2026
Ginkgo Bioworks price targets cut as analysts split on automation lab rollout and cash burn

Analysts have trimmed price targets on Ginkgo Bioworks, with bullish views dropping to $12 from $14 and bearish targets falling to $5 from $9. The revisions reflect mixed sentiment around execution risk and recent business changes. TD Cowen maintained a Buy rating at $12, citing multi-year growth frameworks and improving investor sentiment ahead of 2026 guidance updates. BTIG kept its Sell rating at $5, noting it wants better visibility into how Ginkgo will monetise autonomous labs following the biosecurity business divestiture. Ginkgo recently launched Ginkgo Cloud Lab, a browser-based platform for running benchwork on autonomous lab infrastructure. The company announced collaborations with OpenAI on GPT-5-based biological experiments and with Invaio Sciences on microbial strains for crop protection.

PR Newswire
Mar 2nd, 2026
Ginkgo Bioworks launches cloud lab with AI-powered autonomous infrastructure

Ginkgo Bioworks has launched Ginkgo Cloud Lab, a web-based interface allowing researchers to access the company's autonomous laboratory infrastructure remotely. The platform runs on proprietary Reconfigurable Automation Carts, which combine robotic arms, maglev sample transport and industrial software. The Cloud Lab provides access to over 70 instruments covering biological operations including sample preparation, liquid handling and analytical readouts. Its AI-driven agent, EstiMate, enables scientists to submit protocols in natural language and receive immediate compatibility assessments and pricing. The launch supports Ginkgo's 2026 strategy to transition all R&D services to Nebula, its autonomous lab in Boston, and phase out traditional laboratory benches. The company is inviting researchers from academia and biopharmaceutical firms to test the platform at cloud.ginkgo.bio.

Yahoo Finance
Mar 1st, 2026
Ginkgo Bioworks falls 30% despite Invaio peptide crop protection collaboration and $250M cost savings

Ginkgo Bioworks has reported full-year 2025 results showing lower revenue at $170.16 million and a reduced net loss of $312.76 million, alongside announcing a collaboration with Invaio Sciences on peptide-based crop protection. Despite this, shares declined 30.48% in one day to $6.75. The biotech company has achieved $250 million in annual cost savings and maintains a strong balance sheet with $474 million in cash and no bank debt. Analyst estimates suggest the stock is 32.5% undervalued, with a fair value of $10 per share. However, the company faces significant headwinds, with shares down 22.41% year-to-date and 87.86% over three years. Key risks include slower adoption of its AI and automation platform and margin pressure from underutilised laboratory capacity.

Yahoo Finance
Feb 28th, 2026
Ginkgo Bioworks pivots to autonomous labs, plans biosecurity spin-off amid revenue decline

Ginkgo Bioworks has outlined a 2026 strategy centred on autonomous labs, whilst reporting declining cell engineering revenue and improved cash burn. The company will concentrate capital on its Nebula system in Boston, expand capacity towards 100 racks, and commercialise offerings including Solutions, Datapoints and cloud lab services integrated with AI. Cell engineering revenue fell 26% year-on-year in Q4, with full-year revenue of $133 million versus $174 million in 2024. However, R&D and G&A cuts improved losses, reducing cash burn to $171 million for 2025. Management is guiding cash burn of $125–$150 million for 2026. The company plans to spin off its biosecurity business to outside investors whilst retaining a minority stake, freeing capital for autonomous lab investments.